Wei, S. , Tung, C. et al. Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring. Intestinal Research 2018;16(4):546-553.
- info@buhlmannlabs.ch
- +41 61 487 12 12
Calprotectin Citations
BÜHLMANN IBDoc®: Wong, A, Bourdages, R. et al. Home-based Fecal Calprotectin Testing: A Canadian User Performance Evaluation Study of IBDoc®. CDDW 2018, Feb 09 – 11, 2018. Toronto, ON Canada. Highlights from this Publication “Conclusions. The IBDoc® test kit was understood by participants, with a majority of participants finding it easy to use, with an
Read more
BÜHLMANN fCAL® turbo and IBDoc®: Hejla, J, Theedeb, K, et al. Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis. Practical Laboratory Medicine; 10 (2018) 10-14. PMID: 29234707 DOI: 10.1016/j.plabm.2017.11.002 Highlights from this Publication “This study suggests that IBDoc® is a suitable alternative for the assessment of disease activity in IBD patients. Point of care
Read more
BÜHLMANN fCAL® ELISA: A.Kostas, et al. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World Journal of Gastroenterology; November 2017. PMID: 29151692 DOI: 10.3748/wjg.v23.i41.7387. Highlights from this Publication “In our patient cohort, we were able to define an optimal cut-off FC value of 261 µg/g, which had a strong
Read more
Social Links